Interleukin-6 (Wyeth)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterleukin-6 (Wyeth)
Drug Alias NameSDZ ILS-969BSF-2ILS-969
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-6 receptor alpha subunit agonistsInterleukin-6 receptor subunit beta agonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsThrombocytopeniaOvarian NeoplasmsCarcinoma, Renal Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsThrombocytopeniaOvarian NeoplasmsCarcinoma, Renal Cell +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia